ESR1 and cancer: Utilizing IHC, ER-β has been identified in several human cancer types that were traditionally known to be ER-negative based on previous assays using ER-alpha.-specific antibodies, including carcinomas of the colon, esophagus, stomach, lung, and prostate [16–21].